References
- Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708–14
- Michon J. Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey. Med Pediatr Oncol 2002;39:448–50
- Ruggiero A, Riccardi R. Interventions for anemia in pediatric cancer patients. Med Pediatr Oncol 2002;39:451–4
- Donato H. Erythropoietin: an update on the therapeutic use in newborn infants and children. Expert Opin Pharmacother 2005;6:723–34
- Feusner J, Hastings C. Recombinant human erythropoietin in pediatric oncology: a review. Med Pediatr Oncol 2002;39:463–8
- Guyot D, Margueritte G. Utilisation de l’érythropoïétine recombinante humaine chez l’enfant atteint de cancer [Use of human recombinant erythropoietin in children with cancer]. Arch Pediatr 2005;12:1376–82
- Parsons SK. Oncology practice patterns in the use of hematopoietic growth factors. Curr Opin Pediatr 2000;12:10–7
- Csáki C, Ferencz T, Schuler D, Borsi JD. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer 1998;34:364–7
- Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr 1996;129:656–60
- Razzouk BI, Hord JD, Hockenberry M, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 2006;24:3583–9
- Varan A, Buyukpamukcu M, Kutluk T, Akyuz C. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics 2006;103:E16
- Wagner LM, Billups CA, Furman WL, et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol 2004;22:1886–93
- Bolonaki I, Stiakaki E, Lydaki E, et al. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 1996;13:111–21
- León P, Jiménez M, Barona P, Sierrasesúmaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 1998;30:110–6
- Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994;13:403–10
- Tenenbaum T, Hasan C, Kramm CM, et al. Oncological management of pediatric cancer patients belonging to Jehovah’s Witnesses: a two-institutional experience report. Onkologie 2004;27:131–7
- Yilmaz D, Cetingul N, Kantar M, et al. A single institutional experience: is epoetin alpha effective in anemic children with cancer? Pediatr Hematol Oncol 2004;21:1–8
- Zoubek A, Kronberger M. Early epoetin alfa treatment in children with solid tumors. Med Pediatr Oncol 2002;39:459–62
- Beck MN, Beck D. Recombinant erythropoietin in acute chemo therapy-induced anemia of children with cancer. Med Pediatr Oncol 1995;25:17–21
- Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a random ized, double-blind trial with placebo. J Clin Oncol 1994;12:1058–62
- Case DC, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801–6
- Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2007;19:2865–74
- Del Mastro L, Venturini M, Lionetto R, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 2007;15:2715–21
- Sinclair AM, Todd MD, Forsythe K, et al. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007;110:477–88
- Osterborg A, Aapro M, Cornes P, et al. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007;43:510–9